Prostate cancer management: (2) an update on locally advanced and metastatic disease

S R J Bott, A J Birtle, C J Taylor, R S Kirby

The management of locally advanced prostatic cancer, like localised disease, depends on the tumour characteristics—the stage and Gleason grade, the prostate specific antigen (PSA) level, the age and health of the patient, and based on a multidisciplinary team approach.

LOCALLY ADVANCED PROSTATE CANCER

In the UK, locally advanced prostate cancers account for 40% of prostate cancers at presentation. These include carcinomas where one or two acini have penetrated through the prostatic capsule to those invading adjacent structures including the trigone of the bladder, the rectum, the urethra, and the pelvic side wall. Therapeutic options include external beam radiotherapy (EBRT) (with or without neoadjuvant or adjuvant androgen ablation), androgen ablation alone, or active monitoring.

External beam radiotherapy and androgen ablation

For men receiving EBRT for T3–4 disease long term adjuvant androgen ablation after radiation offers a significant improvement in both metastatic and biochemical relapse rates when compared with short course androgen ablation given immediately before and during radiotherapy. This has translated into improvements in disease-free survival and overall survival at three years in one study, although in other trials this survival advantage was confined to poorly differentiated tumours only.

Androgen ablation involves chemical or surgical orchidectomy. However, reduced libido and increased fatigue are often associated with both these treatments. Non-steroidal antiandrogen monotherapy with bicalutamide 150 mg for T3–4 disease, compared with luteinising hormone releasing hormone (LHRH) agonists has been evaluated in a number of studies. No significant difference has been seen between the two types of drug in terms of overall survival and time to progression, although significant improvements in sexual interest and physical capacity were reported with bicalutamide.

For asymptomatic patients over 70 years old with low grade disease, active monitoring may be a favoured option. Although a significant survival advantage in favour of immediate hormonal therapy was initially demonstrated in a Medical Research Council study, subsequent follow up has shown much less of a survival difference and thus the potential benefits and side effects of early treatment warrant a full patient discussion.

While androgen ablation in patients does delay disease progression the role of EBRT in this context is not known. EBRT probably provides local symptom control in the medium term, though its effect on the long term local symptom control and on survival is unresolved. These issues are currently being addressed in men with T3 disease in the ongoing PR07 trial. This study will also examine the role of EBRT in clinically localised disease with poor prognosis, including men with T2 tumours with Gleason score >8 and PSA >20 ng/ml, or T2 tumours with PSA >40 ng/ml. The results from this trial are awaited.

For selected patients with locally advanced T3 disease, high dose rate iridium brachytherapy together with a shortened course of EBRT as described for poor risk localised prostate cancer, may be considered, to allow dose escalation and improvement of local control rates.

Intermittent hormone therapy

This may be used in the treatment of both locally advanced and metastatic disease. It has been known for some time that patients who stop androgen ablative treatments may have a period of time being symptom-free from their prostate cancer and side effect-free off treatment. Furthermore, they usually respond again to first

Abbreviations: EBRT, external beam radiotherapy; LHRH, luteinising hormone releasing hormone; PSA, prostate specific antigen
line therapy at the time of relapse, deferring the time to the development of hormone independent disease. In locally advanced but asymptomatic recurrent disease, men have a median survival of 7–8 years, and long term hormonal therapy may negatively impact on their quality of life. Studies have used an initial eight months of treatment with androgen ablation and then a variable period of time off treatment, recommencing when the PSA is greater than 10 ng/ml or 20 ng/ml. In an open label, non-randomised study patients who had responded to an LHRH analogue, such that their PSA fell to normal or below normal levels, had their therapy stopped. PSA levels were checked every three months and when the PSA rose to >20 ng/ml on two successive occasions or there was clinical disease progression treatment was restarted. When the PSA was suppressed again treatment was stopped and so on. While the periods off treatment got shorter with successive cycles, Lane et al demonstrated an overall survival benefit when compared with the immediate and deferred androgen ablation groups of the Medical Research Council study. The results of ongoing randomised trails of intermittent therapy versus standard therapy are required before a definitive answer will be known. However, these studies show intermittent therapy may well prolong treatment time as well as reduce the incidence of side effects during the off treatment periods.

**METASTATIC PROSTATE CANCER**

**Androgen ablation**
The first line treatment in a man with symptomatic metastatic prostate cancer is androgen ablation by medical or surgical castration. This has an initial PSA response rate of around 85%, maintained for 12–18 months. No difference in efficacy has been seen between orchidectomy and the use of the LHRH agonists. Patient choice, age, and comorbidity determine which option is favoured.

Although immediate hormonal therapy has shown only a negligible survival benefit in the asymptomatic patient with metastases, there is certainly evidence of a reduction in important complications—including the incidence of spinal cord compression which was reduced from 5% to 2% and ureteric obstruction fell from 11.8% to 7%. The initiation of an LHRH agonist results in a tumour flare, this is inhibited by using a peripheral antiandrogen such as flutamide for two weeks before and two weeks after the first injection. Cyproterone acetate may also be used in this context but is not recommended as long term monotherapy because of potential hepatic toxicity.

**Hormone refractory prostate cancer**
Recurrence after first line hormonal therapy reflects a poor outlook, with a mean survival of nine months. Choices of treatment include maximum androgen blockade or the addition of an oestrogen. Surgical or medical castration is known to reduce circulating testosterone levels by ~90%. In an attempt to reduce the action of adrenal testosterone peripheral antagonists may be added to a LHRH agonist. The outcome of combined androgen blockade (maximum androgen blockade) remains unclear as there is conflicting data, although meta-analyses suggest the benefit to be in the order of 1%–2%, predominately in patients with low metastatic load and good performance status. Stillboestrol 1 mg is widely used in the UK and has shown effective clinical response rates of around 66% in patients with one previous hormonal manipulation and 13% in those with two or more. However, an increase in thromboembolic and cardiovascular side effects are seen and concurrent low dose anticoagulation with warfarin is in common use. The cardiovascular side effects associated with oestrogen therapy are due to clotting factors generated by the metabolism of oestrogens during their first passage through the liver. An interesting newer method of administering oestrogens is the use of intramuscular polyestradiol phosphate or hormone replacement therapy patches. The first pass effect is avoided, reducing the risk of cardiovascular events. Long term and large scale trials are awaited, though oestrogens may play a greater part in the future management of men with advanced stage prostate cancer. Prophylactic nipple radiation reduces the incidence of gynaecomastia seen in patients on oestrogens.

Prednisolone started after failure of first line hormonal therapy has elicited subjective symptomatic response rates of 56% compared with a 46% response rate to flutamide. There was also a biochemical response rate of 21% and 23% respectively, but no difference in overall survival between the two groups.

**Chemotherapy for metastatic disease**
The use of chemotherapy in hormone refractory prostate cancer is the subject of many ongoing studies. Single agent and combination regimens thus far have shown disappointing response rates of <20%. Symptomatic improvements of 29% versus 12% were seen with single agent mitozantrone added to prednisolone when compared with prednisolone alone but no difference in overall survival was seen. Interest is being shown in tyrosine kinase receptor antagonists and other molecular targets. The outcome of ongoing phase II and III are awaited.

**Radiotherapy in metastatic prostate cancer**
Local radiotherapy may be useful for perineal pain, bleeding, or bony pain. Any bony metastases in a weightbearing bone requires plain radiography review to assess the cortical integrity, and orthopaedic assessment if >50% of the cortex is affected, to determine whether prophylactic stabilisation is required. Local radiation may be offered in addition postoperatively, or as an alternative if the patient is unfit for surgical intervention. A single fraction of local radiotherapy is effective for pain relief in symptomatic bony metastases in up to 76% of patients. It may, however, take several weeks before its effect is manifest. Hemibody irradiation is utilised where a large treatment field is required, usually encompassing pelvis and the upper femurs, however this frequently results in diarrhoea and nausea.

Strontium-89 as an intravenous injection may be used for pain control in widespread bony metastases. It may be associated with an initial pain flare but approximately 10% of treated patients do experience a complete resolution of pain. However, the presence of any critical metastases potentially able to cause spinal cord compression must be excluded, as strontium may cause oedema at these sites. In addition, the treatment commonly produces prolonged myelosuppression, particularly thrombocytopenia, and in patients with already depleted marrow reserves, either due to disease or treatment, this can be problematic. It may also limit future treatment options such as chemotherapy because of its side effects.

**Bisphosphonates**
Bone complications in prostate cancer occur as a result of skeletal metastases, long term treatment with androgen withdrawal and following radiotherapy. Bisphosphonates, now widely used in breast cancer, have been shown to reduce bony pain in prostate cancer for 2–3 weeks after a single intravenous infusion, in up to 30% of patients. More promising results were recently demonstrated with zoledronic acid, the most potent bisphosphonate. The authors reported fewer skeletal events compared with placebo (44.2% vs 33.2%, 95% confidence interval –20.3% to −1.8%, p = 0.02) after a 15 minute infusion of zoledronic acid every three weeks. The median time to first skeletal event was 321 days.
with placebo compared with 363 days for patients receiving 4 mg zoledronic acid. Bisphosphonates act by decreasing the rate of bone turnover, reducing the number of osteoclasts, their recruitment, lifespan and activity.

The patient with metastatic disease reflects the need for an integrated multidisciplinary approach to allow symptomatic control. Early involvement of hospital and community based palliative care teams is essential and easy access to both oncology and urology services remains vital.

CONCLUSIONS

Men with more advanced disease can be treated successfully by androgen ablation, though this is usually a holding procedure before eventual disease relapse. Disease relapse may be deferred by intermittent hormonal therapy; results of trials are awaited before this becomes routine. In the meantime bisphosphonates maybe used to prevent or delay bony complications. The role of chemotherapy has yet to be established though radiotherapy is used to control primary local disease, skeletal metastases, and prevent breast side effects. Further developments in our understanding of the genetics of this disease will allow the identification of new molecular markers and novel therapeutic targets.

Authors’ affiliations
R S Kirby, St George’s Hospital, London

REFERENCES